Protocol consultation from an operator who's seen what scales.

Most clinics that decide to add peptide therapy run into the same problem early — the compounds work, but the operational sequencing around them is unclear. Which compound for which indication. What starting dose for which patient profile. How to stack a recovery protocol against a longevity protocol against a GLP-1 protocol without creating adverse events or patient confusion. Whether to source a given compound through a 503A partner or a 503B partner. How to brief the clinical staff so the protocols hold up across multiple prescribers. Peptide Protocol Consultation at Revival RX Partners exists to answer those questions from an operator who has been inside enough peptide programs to know what scales and what stalls.

The service is the third of Revival's three services. It sits alongside Sourcing and Marketing under the same operator relationship — Brad Fogeltanz personally runs every consultation engagement. Consultation is bundled in the Concierge tier ($1,500/month) and available per-engagement for clinics on Standard sourcing accounts who want the protocol layer without the full bundle.

What consultation actually covers

Consultation is scoped against what the clinic is actually trying to do — launching a peptide program, adding a second protocol to an existing program, expanding into a new indication, or troubleshooting a protocol that isn't generating retention. The scope of any engagement is decided on the intro call. The core areas the service covers:

• Protocol design — compound selection per indication (weight management, recovery, longevity, sleep, body composition), evidence base review, contraindication mapping against the clinic's typical patient profile, and the protocol document the clinical team works against.
• Dosing review — starting dose recommendations, titration paths, max dose ceilings, and how to handle the dosing decisions that fall outside standard protocols (titration speed for patients with adverse response, dose pauses, restart sequencing after a break).
• Stack architecture — how to combine compounds across protocols. Recovery stacks (BPC-157 + TB-500), longevity stacks (NAD+ + growth hormone secretagogue), and the sequencing of compound introductions across a single patient's program over six and twelve months.
• 503A versus 503B routing per compound — which compound the clinic should source patient-specific through a 503A partner versus office-use inventory through a 503B partner. The routing decision is consequential and Revival treats it as a per-compound decision rather than a clinic-wide default.
• Operational sequencing — the order to launch protocols, the staff training the protocols require, the patient education materials the clinic needs in place, and the intake-to-administration workflow that the clinical team executes against.
• New-compound briefings — as the catalog evolves and as the regulatory landscape changes, Concierge clinics get the first briefing on which new compounds are worth integrating into their program and which are not.

How consultation is delivered

Consultation runs in two formats. The Concierge bundle includes ongoing consultation as part of the monthly partnership — scheduled clinical review calls, direct access to Brad for protocol questions as they come up, and the new-compound briefings as the catalog evolves. The per-engagement format is for clinics on Standard sourcing accounts who want consultation on a specific protocol question without the full bundle. Per-engagement scope and pricing are quoted on the intro call against the specific question or build the clinic is working through.

Every consultation engagement is delivered by Brad personally. There is no account-manager handoff and no junior consultant doing the work under a senior consultant's name. The methodology depends on operator-level pattern recognition across the peptide industry — the engagement structure exists to keep that pattern recognition close to the clinic's specific operational questions.

Methodology

The methodology is operator-driven rather than literature-driven. The peptide category has a thinner peer-reviewed evidence base than most clinical categories — most compounds in active use are FDA-approved for specific indications and off-label for the indications clinics actually run them for, or compounded against the practice of medicine without FDA approval as new drugs. Consulting purely from the published literature produces conservative protocols that don't reflect how the compounds actually behave in real clinic operations.

The operator methodology is different. It starts from what Brad has watched scale across the partner-clinic roster and the peptide-industry footprint: which compounds generate the cleanest patient response, which dose ranges produce the fewest adverse calls, which stack combinations compound retention into LTV, which protocols generate the most provider confidence at the prescriber level, and which sourcing decisions translate clinical decisions into operationally sustainable workflows. The protocols recommended in consultation reflect that pattern recognition, layered on top of the published evidence base rather than instead of it.

Vertical-specific protocols

Peptide programs look different across clinic verticals, and the consultation work reflects that. The same compound runs through a med spa, a TRT clinic, and a functional medicine practice in three different ways — different patient profiles, different intake workflows, different stack logic, different operational sequencing. The vertical-specific notes Revival applies during consultation:

• Med spa — GLP-1 dominates volume, with NAD+ and BPC-157 as the natural post-procedure recovery cross-sell. Protocols favor 503A patient-specific dispensing for titration flexibility, with 503B inventory for in-office NAD+ IV programs. Patient acquisition leans on the existing aesthetic patient base. See /for-med-spas for the full vertical detail.
• TRT clinic — growth hormone secretagogues (sermorelin, ipamorelin, CJC-1295) are the natural second-protocol expansion after a stable TRT program. Recovery peptides cross-sell to active patient demographics. Protocols favor 503A patient-specific compounding for individualized dosing. See /for-trt-clinics for the full vertical detail.
• Functional medicine — protocols are highly individualized against the patient's broader treatment plan. Custom physician-supervised compounding through 503A partners is dominant. Stack architecture is more complex because the peptide protocol sits inside a larger treatment plan. See /for-functional-medicine for the full vertical detail.
• Wellness centers — broader catalog with multiple indications running in parallel. Operational sequencing matters more than protocol depth — keeping the staff trained on the active protocols is the constraint that gates how many compounds can run at once. See /for-wellness-centers for the full vertical detail.

When consultation makes sense

Consultation makes sense for clinics in three situations. First, clinics considering peptide therapy that need a clinical and operational baseline before committing — the engagement compresses the time from decision to launch by months. Second, clinics with an active peptide program that need help on a specific protocol decision (a new compound, a new indication, a routing question, a stack architecture question). Third, clinics scaling a program that need ongoing clinical and commercial review as the protocols and the patient base evolve.

Consultation does not replace the clinic's medical director. The clinical team makes prescribing decisions and signs off on protocols — consultation is an operational and clinical pattern-recognition layer on top of that authority, not a substitute for it. The boundary is intentional. Revival does not provide medical advice to patients and does not direct prescribing decisions.